ALX Oncology Holdings Inc. (ALXO)
ALXONASDAQ-GSBiotechnology: Pharmaceutical Preparations
$1.20
-0.0400 (-3.23%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $160.53m
- P/E
- –
- EPS, last 4 quarters
- $-1.13
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8617 to $2.66
- Average volume
- 1.28m
- Previous close
- $1.24
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $4.33, +260.8% from here
Earnings
next estimate $-0.1400Next report
Sep 2025
-10.8%
Dec 2025
-10.5%
Mar 2026
-13.3%
Jun 2026
+13.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$22.53m | -$23.02m | -$18.97m | -$18.03m |
| Net income | -$22.14m | -$22.85m | -$17.93m | -$17.97m |
News
8 latest- BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?Zacks · Jul 9, 2026
- ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug ProgramsMarketBeat · Jun 3, 2026
- ALX Oncology (ALXO) Q1 2026 Earnings TranscriptThe Motley Fool · Jun 1, 2026
- ALX Oncology Q1 Earnings Call HighlightsMarketBeat · May 8, 2026
- bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?Zacks · Apr 16, 2026
- ALX Oncology Holdings (ALXO) Price Target Increased by 38.00% to 4.69Fintel · Mar 27, 2026
- Wells Fargo Initiates Coverage of ALX Oncology Holdings (ALXO) with Overweight RecommendationFintel · Mar 19, 2026
- ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDAZacks · Mar 18, 2026
The company
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology's second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- alxoncology.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.